^
Association details:
| Biomarker: | CD52 overexpression |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
CD52 mRNA expression predicts prognosis and response to immune checkpoint blockade in melanoma
Published date:
11/17/2023
Excerpt:
Higher CD52 mRNA expression was associated with favorable OS (hazard ratio (HR) = 0.820, [95% CI 0.734-0.916], p < .001) in non-ICB-treated melanoma and with PFS (HR = 0.875, [95% CI 0.775-0.989], p = .033) and DC (p = .005) in ICB-treated melanoma….CD52 expression is associated with features of ICB response in melanoma....Altogether, CD52 represents an interesting target warranting further investigation in the context of tumor-immune response and therapy response to ICB in melanoma.
DOI:
10.1111/pcmr.13151
